Regeneron Pharmaceuticals Inc (REGN)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	4,412,600	4,654,500	4,321,700	3,857,800	3,953,600	3,991,100	4,299,000	4,182,700	4,338,400	5,370,300	5,686,800	7,933,600	8,075,300	6,995,500	6,205,400	4,003,800	3,513,200	3,156,000	2,983,500	2,279,300
Total assets	US$ in thousands	37,759,400	37,441,900	36,086,800	34,369,600	33,080,200	32,163,300	30,657,500	30,059,900	29,214,500	27,677,800	27,205,800	26,348,700	25,434,800	23,671,500	21,485,900	17,772,200	17,163,300	16,084,000	14,428,700	15,757,500
ROA		11.69%	12.43%	11.98%	11.22%	11.95%	12.41%	14.02%	13.91%	14.85%	19.40%	20.90%	30.11%	31.75%	29.55%	28.88%	22.53%	20.47%	19.62%	20.68%	14.46%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $4,412,600K ÷ $37,759,400K
= 11.69%

Regeneron Pharmaceuticals Inc's return on assets (ROA) has shown fluctuations over the past few quarters. The ROA increased consistently from March 2020 to December 2021, reaching a peak of 31.75% by the end of December 2021. This upward trend indicates that the company was effectively utilizing its assets to generate profits during this period.

However, starting from March 2022, the ROA began to decline steadily, with a significant drop by December 2023 to 11.95%. This downward trend continued into 2024, with ROA ranging between 11.22% to 12.43% for the quarters ending in September and December 2024. This decline suggests a potential decrease in the company's efficiency in generating profits from its assets.

Overall, the ROA trend for Regeneron Pharmaceuticals Inc indicates a period of strong asset utilization and profitability followed by a decline in efficiency. Further analysis would be needed to understand the factors contributing to these fluctuations and to assess the company's future performance.